Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma

Role of eIF6 in Modulating Response to BRAF Inhibitors and Acquired Resistance in Cutaneous Melanoma

Saved in:

Bibliographic Details
Main Authors:	G. Kyriakopoulos, A. Petropoulou, A. Bania, V.S. Stamatakis, A. Alexiou, A. Anastogianni, S. Georgiou, C. Stathopoulos, K. Grafanaki
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001241
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
by: Bilgen Gençler, et al.
Published: (2016-01-01)

Evolution of Acquired Drug Resistance in BRAF-Mutant Melanoma
by: Josué Ballesteros-Álvarez, et al.
Published: (2024-10-01)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case
by: V. E. Askarov, et al.
Published: (2025-07-01)

Genetic and Epigenetic Interconnections Between Atopic Dermatitis, Allergic Rhinitis, and Rhinitis with Nasal Polyps
by: Alexandra Danielidi, et al.
Published: (2025-03-01)

Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
by: Grant A McArthur, et al.
Published: (2025-05-01)

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆
by: G.K. In, et al.
Published: (2024-12-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Predicting BRAF Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis
by: Oleksandr Dudin, et al.
Published: (2024-01-01)

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition
by: Danielle G. Carvalho, et al.
Published: (2025-07-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
by: Ariane Fizazi, et al.
Published: (2024-11-01)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
by: Caitlyn N. Myrdal, et al.
Published: (2020-01-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
by: Barbara Montico, et al.
Published: (2025-02-01)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
by: Alireza Azimi, et al.
Published: (2018-03-01)

Rescue of cell cycle progression in BRAF inhibitor–resistant human melanoma by a chromatin modifier
by: Antoni X Torres-Collado, et al.
Published: (2017-09-01)

A Melanosis Patient with Primary Unknown Metastatic Melanoma: Successful Treatment with BRAF/MEK Inhibitors
by: Faruk Tas
Published: (2025-04-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
by: Ryan J. Sullivan, et al.
Published: (2011-01-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
by: Antoine Toubert, et al.
Published: (2020-10-01)

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
by: Julie Delyon, et al.
Published: (2024-11-01)

Melanoma genomics – will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2024-09-01)

Circulating tumor DNA: a promising biomarker in stage III BRAF+ melanoma
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Exploiting mitochondrial dysfunction to overcome BRAF inhibitor resistance in advanced melanoma: the role of disulfiram as a copper ionophore
by: Bolun Zhao, et al.
Published: (2025-07-01)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
by: Marjon A Smit, et al.
Published: (2014-12-01)

Correction: Melanoma genomics– will we go beyond BRAF in clinics?
by: Justyna Mirek, et al.
Published: (2025-02-01)

Mutaciones de KIT, NRAS y BRAF en melanoma
by: Luz de María Díaz-Granados, et al.
Published: (2019-08-01)

Patient treatment preferences in unresectable/metastatic BRAF-mutated melanoma: a qualitative study
by: T. Amaral, et al.
Published: (2024-01-01)

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
by: Marloes Faut, et al.
Published: (2018-06-01)

Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis
by: Mathilde Berger, et al.
Published: (2020-04-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

Elevated lactate dehydrogenase in adjuvant BRAF and MEK inhibitor therapy does not have diagnostic significance in detecting melanoma recurrence
by: Łukasz Galus, et al.
Published: (2025-03-01)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01)

Multiple Cutaneous Melanomas
by: Carmen Cristina DRAGHICI, et al.
Published: (2019-12-01)

Metabolic parameters on baseline and early [18F]FDG PET/CT as a predictive biomarker for resistance to BRAF/MEK inhibition in advanced cutaneous BRAFV600-mutated melanoma
by: Bernies van der Hiel, et al.
Published: (2025-05-01)

Anticancer Quinolinol Small Molecules Target Multiple Pathways to Promote Cell Death and Eliminate Melanoma Cells Resistant to BRAF Inhibitors
by: Xinjiang Wang, et al.
Published: (2025-06-01)

MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review
by: Yanling Zhang, et al.
Published: (2025-04-01)

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
by: Jonas K. Oddershede, et al.
Published: (2025-04-01)